Desoxyn vs Adderall: Why One Is Rarely Prescribed

Desoxyn (methamphetamine hydrochloride) and Adderall (mixed amphetamine salts) are both FDA-approved stimulants for ADHD, but Desoxyn is the actual pharmaceutical form of methamphetamine, and it is rarely prescribed today for reasons this guide explains. This is one of the more misunderstood drug comparisons online, since “methamphetamine” carries heavy street-drug associations that can obscure what the FDA-approved medicine actually is and how it differs from the far more commonly used Adderall.

This is general information, not medical advice. Both are Schedule II controlled substances with serious cardiovascular and abuse warnings.

Table of Contents

Desoxyn vs Adderall at a glance

	Desoxyn (methamphetamine)	Adderall (mixed amphetamine salts)
Active drug	Methamphetamine hydrochloride	Dextroamphetamine and amphetamine salts (3:1 ratio)
FDA-approved for	ADHD (pediatric patients 6+)	ADHD, narcolepsy
Former obesity indication	Removed from labeling in 2019	Never had an obesity indication
How commonly prescribed	Rarely; other stimulants strongly preferred	Very commonly prescribed
Schedule	II	II
Initial FDA approval	1943	1960s (dextroamphetamine); Adderall brand 1996

What each is approved for

Desoxyn is currently indicated only for the treatment of ADHD in pediatric patients 6 years of age and older. It is worth noting explicitly: Desoxyn’s older labeling also covered short-term weight loss (exogenous obesity) alongside diet, but the FDA approved removal of that obesity indication from the labeling in 2019, following a 2018 agency notice. Desoxyn today has one approved use: pediatric ADHD.

Adderall (immediate-release) and Adderall XR are indicated for ADHD, and immediate-release Adderall is also approved for narcolepsy, a sleep disorder causing excessive daytime sleepiness. Adderall has no obesity indication and never has.

Why Desoxyn is rarely prescribed

Despite carrying a real, current FDA approval for ADHD, Desoxyn is not commonly prescribed. A drug comparison resource states plainly that methamphetamine (Desoxyn) is FDA-approved to treat ADHD, but it’s not commonly prescribed, as other medications for ADHD are more preferred, including Adderall. The DEA’s own drug fact sheet on methamphetamine confirms there is currently only one legal methamphetamine product, Desoxyn, now marketed in a small range of tablet strengths, with very limited use in ADHD treatment.

The reasons for this rarity, drawn from clinical and regulatory context, generally include:

Stigma and diversion concerns. Methamphetamine’s profile as a widely misused illicit drug makes prescribers and pharmacies understandably cautious, even though the pharmaceutical product is a regulated, quality-controlled medicine distinct from street methamphetamine.
Equally effective, more familiar alternatives exist. Amphetamine-based drugs like Adderall and lisdexamfetamine (Vyvanse), and methylphenidate-based drugs like Concerta and Focalin, are extensively studied, widely available, and generally preferred by prescribers with no compelling reason to reach for methamphetamine instead.
Narrower current indication. With the 2019 removal of the obesity indication, Desoxyn’s approved use is now limited strictly to pediatric ADHD, further shrinking any scenario where it might be specifically chosen.
Regulatory and pharmacy friction. Some pharmacies are reluctant to stock or dispense it given its street-drug association, adding a practical barrier beyond the clinical decision itself.

How the two drugs compare chemically

Both are amphetamine-class stimulants that work by blocking the reuptake of norepinephrine and dopamine into the presynaptic neuron and increasing the release of these chemicals into the surrounding space, the shared amphetamine mechanism described in both labels. Methamphetamine and amphetamine are closely related chemically (methamphetamine has an added methyl group), and their appropriate medical use follows essentially the same pharmacological logic for ADHD, though methamphetamine is generally considered to have somewhat higher lipid solubility and a faster, more pronounced central nervous system entry, part of why it carries a stronger illicit-use reputation at non-medical doses.

Dosing

Desoxyn is administered orally once daily or in two divided doses, with the label specifically advising against administration late in the evening because of insomnia risk. Historical dosing references describe a usual effective dose around 20 to 25 mg daily, given in divided doses; current pediatric ADHD dosing is individualized and started low.

Adderall XR is a once-daily extended-release capsule; immediate-release Adderall is typically dosed once or twice daily depending on response and duration of effect needed.

Side effects and warnings

Both carry boxed warnings for high abuse potential and for serious cardiovascular adverse reactions, including sudden death, associated with amphetamine misuse. Desoxyn’s label specifically lists contraindications including glaucoma, advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, and a history of drug abuse or an agitated state, cautions that apply broadly across the amphetamine class but are spelled out in detail in its label. Desoxyn’s common adverse reactions include palpitation, dizziness, insomnia, tremor, headache, diarrhea, and dry mouth, essentially the standard amphetamine-class list also seen with Adderall.

Both drugs can lower the seizure threshold, can suppress growth with long-term pediatric use, and require pretreatment cardiovascular screening and monitoring of blood pressure and heart rate.

Who each might suit

In practice, this comparison rarely comes down to genuine clinical equivalence. Adderall (or another amphetamine or methylphenidate stimulant) is the default choice for essentially all patients who are candidates for stimulant ADHD treatment, given its established track record, broader familiarity among prescribers and pharmacies, and (for Adderall specifically) the additional narcolepsy indication. Desoxyn’s niche is narrow: it may occasionally be considered when a patient has already tried and not tolerated other stimulants, though even this scenario is uncommon in current practice, and any decision to use it should come from a specialist familiar with its particular regulatory and practical considerations.

Frequently asked questions

Is Desoxyn real methamphetamine?

Yes. Desoxyn’s active ingredient is methamphetamine hydrochloride, the same drug class as illicit methamphetamine, but manufactured, quality-controlled, and dosed as an FDA-approved prescription medicine, distinct from street methamphetamine in purity, dosing, and legal status.

Why isn’t Desoxyn used for weight loss anymore?

The FDA approved removal of Desoxyn’s exogenous obesity indication from its labeling in 2019, following a 2018 agency notice. It is now approved only for pediatric ADHD.

Is Desoxyn stronger than Adderall?

They are both amphetamine-class stimulants with a similar general mechanism. Methamphetamine has somewhat different pharmacokinetic properties, but “stronger” is not a simple, established clinical ranking between the two at properly prescribed doses; potency differences are managed through dosing, not by one drug being categorically more powerful in a therapeutic sense.

Why would a doctor ever prescribe Desoxyn over Adderall?

This is uncommon in current practice. It might be considered in rare cases after other stimulants have failed, but Adderall and other more commonly used stimulants are the default first choices for essentially all patients who are candidates for stimulant treatment.

Are Desoxyn and Adderall both controlled substances?

Yes, both are Schedule II controlled substances under federal law, reflecting their high potential for abuse alongside their accepted medical use.

The obesity indication removal, in more detail

Before 2019, Desoxyn’s label included an indication for exogenous obesity as a short-term (a few weeks) adjunct to caloric restriction, similar to how several older amphetamine products were once positioned for weight loss. The FDA’s own drug shortage and labeling reviews of older stimulant obesity indications, part of a broader agency reassessment of amphetamine-class weight-loss drugs approved decades earlier under looser evidentiary standards, led to the sNDA approval letter dated April 12, 2019, that removed this indication from Desoxyn’s label. This mirrors a pattern seen across several old-generation amphetamine obesity drugs during that period, as the FDA moved to align older labels with modern evidence standards for weight management, where safer, better-studied options are now generally preferred. Today, Desoxyn’s labeling is unambiguous: it is indicated only for ADHD in patients 6 and older.

How pharmacies and prescribers actually treat Desoxyn today

Because of methamphetamine’s Schedule II status and street-drug reputation, some pharmacies choose not to stock it at all, and some prescribers avoid it by default even when it could theoretically be an appropriate option, simply because more familiar, equally effective alternatives exist without the added scrutiny, patient anxiety, or pharmacy friction that dispensing a “methamphetamine prescription” can create. This is a practical and cultural reality of prescribing, separate from the pharmacology itself. Patients occasionally report needing to call multiple pharmacies to find one willing to fill a Desoxyn prescription, an inconvenience essentially unique to this drug among ADHD medications.

Pharmacy shelf illustration showing a Desoxyn bottle set apart representing its rarity

Amphetamine vs methamphetamine: the actual chemical difference

The two molecules differ by a single methyl group attached to the amphetamine nitrogen atom. This small structural change increases methamphetamine’s lipid solubility, which affects how readily it crosses the blood-brain barrier and contributes to its reputation for a faster, more intense subjective effect at recreational (non-medical) doses. At properly prescribed therapeutic doses for ADHD, however, this difference is managed through the prescribed dose and formulation rather than translating into a fundamentally different treatment experience; the FDA-approved medical use of both is grounded in the same general norepinephrine/dopamine reuptake-blocking mechanism.

Frequently asked questions (continued)

Will a Desoxyn prescription show up differently on a drug test than Adderall?

Standard amphetamine drug screens typically detect both amphetamine and methamphetamine, though confirmatory testing can distinguish which specific substance was used. Patients prescribed either medication should keep a copy of their prescription available in case a workplace or other drug screen flags a positive result.

Is Desoxyn ever prescribed for adults?

The current label’s approved indication is specifically pediatric patients 6 years and older; ADHD treatment decisions for adults typically default to other, more established stimulant or non-stimulant options given Desoxyn’s narrow current labeling and limited use in practice.

Why would the FDA still allow a methamphetamine drug on the market at all?

Desoxyn has a long-standing, real FDA approval for pediatric ADHD, and the agency’s role is to weigh benefit against risk for an approved medical use under controlled, prescribed conditions, which is a different question from the risks of illicit methamphetamine use. Its Schedule II status reflects that a real abuse potential exists alongside its accepted medical use.

Historical context: Desoxyn’s long history on the market

Desoxyn has been available since 1943, making it one of the oldest stimulant medications still carrying an active FDA approval, predating Ritalin (methylphenidate, approved 1955) and Adderall’s amphetamine-salt combination by decades. Methamphetamine was actually used clinically before amphetamine’s ADHD-adjacent uses were well established, including historical (and now abandoned) uses such as a nasal decongestant component and in various now-discontinued combination products. Its continued presence on the market today, even in a narrow role, reflects grandfather-era FDA approval status rather than modern, active promotion; it received its original approval decades before current standards for large randomized controlled trials were required for new drug approvals.

How Desoxyn is actually manufactured and regulated today

Because Desoxyn is a Schedule II controlled substance, its manufacture is regulated by the DEA under strict production quotas, the same system that governs how much raw amphetamine and methylphenidate can be produced annually in the US for all pharmaceutical uses combined. This means supply can be affected by broader DEA quota decisions, separate from ordinary drug-shortage dynamics that affect other medications. Patients relying on it should be aware that, given its low prescription volume, some pharmacies may need to special-order it rather than keeping it in routine stock.

What patients switching from Adderall to Desoxyn (or vice versa) should know

Because there is no standard milligram-for-milligram conversion table published between methamphetamine and mixed amphetamine salts in current labeling, any switch between the two should start with a fresh, conservative dose under medical supervision rather than an assumed equivalent dose, similar to how switches between different stimulant classes are generally handled throughout ADHD treatment. Patients should also expect that insurance prior authorization requirements may be more involved for Desoxyn than for far more commonly prescribed Adderall, given its narrower approved use and lower typical prescribing volume.

Frequently asked questions (continued, second round)

How old is Desoxyn as a medication?

It was first approved in 1943, making it one of the oldest stimulant medications still carrying an active FDA approval today, predating both methylphenidate and Adderall.

Why might a pharmacy not have Desoxyn in stock?

Given its low prescription volume relative to more commonly used stimulants, some pharmacies may need to special-order it rather than keep it routinely stocked, and DEA production quotas for controlled stimulants can also affect availability.

Can I switch directly from Adderall to Desoxyn at an equivalent dose?

There is no standard published conversion table between the two. Any switch should start with a conservative dose adjusted by the prescriber rather than assuming direct equivalence.

Practical tips relevant to this comparison

If a prescriber does suggest Desoxyn, ask specifically why it is being chosen over more commonly used stimulants; given how rarely it’s prescribed, understanding the reasoning helps set realistic expectations about pharmacy access and insurance coverage.
Call ahead to confirm pharmacy stock before showing up with a Desoxyn prescription, since low-volume stocking means it is more often special-ordered than kept on the shelf.
Avoid taking either medication in the evening; both list insomnia as a common side effect, and late dosing is one of the most common preventable causes of sleep disruption during stimulant treatment.
Disclose any history of heart problems, high blood pressure, glaucoma, or thyroid disease before starting either drug, since these appear as contraindications or cautions on both labels.
Keep either medication locked and tracked given its Schedule II status and documented abuse potential, particularly in households with teenagers or other people who might misuse it.